Loading clinical trials...
Loading clinical trials...
A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
February 2, 2026
Primary Completion Date
June 1, 2027
Completion Date
December 1, 2027
Last Updated
March 10, 2026
44
ESTIMATED participants
GR1803 injection
BIOLOGICAL
Lead Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT06828042
NCT06821659
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions